NexImmune (STU:7370) DeferredTaxAndRevenue: €0.00 Mil (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:7370 NexImmune Inc STU:7370
33 GF Score
Price €4.55
View Full Analysis

What is NexImmune DeferredTaxAndRevenue?

NexImmune STU:7370 33 DeferredTaxAndRevenue is €0.00 Mil as of Jun. 2024. GuruFocus rates STU:7370 with a GF Score™ of 33/100.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

NexImmune's current deferred tax and revenue for the quarter that ended in Jun. 2024 was €0.00 Mil.

NexImmune DeferredTaxAndRevenue Related Terms

NexImmune DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for NexImmune's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NexImmune DeferredTaxAndRevenue Chart

NexImmune Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
DeferredTaxAndRevenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

NexImmune Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:7370
33GF Score
NexImmune Inc STU:7370
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of €0.00 Mil mean?
NexImmune (STU:7370) has a DeferredTaxAndRevenue of €0.00 Mil as of Jun. 2024. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on NexImmune.
Is NexImmune's DeferredTaxAndRevenue too high?
NexImmune's current DeferredTaxAndRevenue is €0.00 Mil. Overall, NexImmune has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does NexImmune's DeferredTaxAndRevenue compare to PPCBD and ENDV?
NexImmune's DeferredTaxAndRevenue of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on NexImmune. NexImmune's current DeferredTaxAndRevenue is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NexImmune stock overvalued right now?
NexImmune (STU:7370) has a current DeferredTaxAndRevenue of €0.00 Mil. The current DeferredTaxAndRevenue is €0.00 Mil. NexImmune's overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For NexImmune (STU:7370), the current DeferredTaxAndRevenue is €0.00 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NexImmune Business Description

Address 9119 Gaither Road, Gaithersburg, MD, USA, 20877
NexImmune Inc is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.
33GF Score

Get the complete analysis for STU:7370

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.55
Price